Sanus Biotech

Sanus Biotech is a South Korean biopharmaceutical company dedicated to developing innovative therapeutics for metabolic and age-related diseases by targeting Sirtuin 1 (SIRT1). The company leverages its proprietary discovery platform to identify potent and selective small molecule SIRT1 activators that aim to mimic the health benefits of caloric restriction and exercise. Their current pipeline focuses on high-prevalence conditions including obesity, Type 2 Diabetes, sarcopenia, and non-alcoholic steatohepatitis (NASH). By modulating cellular energy metabolism and stress responses, Sanus Biotech seeks to provide disease-modifying treatments that restore metabolic homeostasis. The company is headquartered in Daejeon and is supported by several regional venture capital partners.